| 查看: 1539 | 回复: 17 | |||
| 当前只显示满足指定条件的回帖,点击这里查看本话题的所有回帖 | |||
[交流]
开发一种新药的惊人花费(The truly staggering cost of inventing new drugs)
|
|||
|
原文链接:http://bioluminor.biomart.cn/news/2770272.htm During the Super Bowl, a representative of the pharmaceutical company Eli Lilly posted the on the company’s corporate blog that the average cost of bringing a new drug to market is $1.3 billion, a price that would buy 371 Super Bowl ads, 16 million official NFL footballs, two pro football stadiums, pay of almost all NFL football players, and every seat in every NFL stadium for six weeks in a row. This is, of course, ludicrous. The average drug developed by a major pharmaceutical company costs at least $4 billion, and it can be as much as $11 billion. The drug industry has been tossing around the $1 billion number for years. It is based largely on a study (supported by drug companies) by Joseph DiMasi of Tufts University. It’s a nice number for the pharmaceutical industry, because it seems to justify the idea that medicines should be pricey (and increasingly, they can be very pricey, costing tens of thousands of dollars per patient per year) without making it seem that inventing new medicines is so expensive an endeavor as to be ultimately futile. But as Bernard Munos of the InnoThink Center for Research In Biomedical Innovation has noted, just adjusting that estimate for current failure rates results in an estimate of $4 billion in research dollars spent for every drug that is approved. But Munos showed me another figure, where he divided each drug company’s R&D budget by the average number of drugs approved. This was far more dramatic. The range of money spent is stunning. AstraZeneca has spent $12 billion in research money for every new drug approved, as much as the top-selling medicine ever generated in annual sales; Amgen spent just $3.7 billion. At $12 billion per drug, inventing medicines is a pretty unsustainable business. At $3.7 billion, you might just be able to make money (a new medicine can probably keep generating revenue for ten years; invent one a year at that rate and you’ll do well). There are lots of expenses here. A single clinical trial can cost $100 million at the high end, and the combined cost of manufacturing and clinical testing for some drugs has added up to $1 billion. But the main expense is failure. AstraZeneca does badly by this measure because it has had so few new drugs hit the market. Eli Lilly spent roughly the same amount on R&D, but got twice as many new medicines approved over that 15 year period, and so spent just $4.5 billion per drug. Wanting to make this even more rigorous, Forbes (that would be Scott DeCarlo and me) took Munos’ count of drug approvals for the major pharmas and combined it with their research and development spending as reported in annual earnings filings going back fifteen years, pulled from a Thomson Reuters database using FactSet. We adjusted all the figures for inflation. Using both drug approvals and research budgets since 1997 keeps the estimates being skewed by short-term periods when R&D budgets or drug approvals changed dramatically. The range of money spent is stunning. AstraZeneca has spent $12 billion in research money for every new drug approved, as much as the top-selling medicine ever generated in annual sales; Amgen spent just $3.7 billion. At $12 billion per drug, inventing medicines is a pretty unsustainable business. At $3.7 billion, you might just be able to make money (a new medicine can probably keep generating revenue for ten years; invent one a year at that rate and you’ll do well). There are lots of expenses here. A single clinical trial can cost $100 million at the high end, and the combined cost of manufacturing and clinical testing for some drugs has added up to $1 billion. But the main expense is failure. AstraZeneca does badly by this measure because it has had so few new drugs hit the market. Eli Lilly spent roughly the same amount on R&D, but got twice as many new medicines approved over that 15 year period, and so spent just $4.5 billion per drug. |
» 猜你喜欢
2026年申博药学专业
已经有1人回复
药学专硕申博
已经有18人回复
药物学论文润色/翻译怎么收费?
已经有223人回复
可能上不了岸?有条件的可以考虑其他出路
已经有0人回复
医药研发数据库资源
已经有4人回复
分子对接相关经验分享
已经有0人回复
分子对接相关经验分享
已经有0人回复
2026生物医药产业发展大会
已经有0人回复
国青中了
已经有23人回复
:D多个国家或地区的农药法规&登记情况查询网站
已经有0人回复
» 抢金币啦!回帖就可以得到:
2027年能源利用与优化调度国际会议(EUOE 2027)
+1/857
广州征女友
+2/162
吉林大学物理学院李亮教授非晶纳米晶方向申请考核博士招生
+2/151
帮征女友,以结婚为目的,非诚勿扰 【上海】
+1/74
厦门大学具身智能传感器与人机交互实验室招收2027级博士研究生
+5/55
福州大学生物科学与工程学院博士研究生招生(生物医学工程/生物与医药)
+1/40
北京化工大学材料与科学工程学院高洋洋招收2027级博士生
+1/31
兰州大学2027级申请-考核制博士 药化、基因工程、生物材料方向
+1/21
香港浸会大学史珏教授小组诚招博士生(研究方向:肿瘤免疫及肿瘤类器官)
+2/20
浙江大学医学院附属第一医院(国家重点实验室)微生态与代谢团队招聘技术员及助理
+1/17
福建师范大学多孔框架团队2027年博士招生!!
+1/16
中科院地质地球所招收博士/博士后,待遇优厚!!!!
+1/14
美国Clemson大学 Liu Sheng课题组 biophysics 招收2027级博士生
+1/13
南京工业大学柔性电子(未来技术)学院招2027申请考核制博士生(钙钛矿太阳能方向)
+1/9
中国科大-合肥国家实验室冷原子量子网络团队招聘启事
+2/8
2026秋福建师范大学化学与材料学院团队博士/硕士招生
+1/8
诚挚招收全日制博士!!!中国农业科学院麻类研究所谭志坚研究员课题组招收博士
+1/8
南京理工大学邱颖宁/冯延晖课题组招收博士生2~3名(能源动力方向)
+1/7
华南师范大学路猛课题组招聘博士后/青年英才
+1/5
华中师范大学化院曹郁教授组招收2027级“申请-考核”制博士生
+1/4
9楼2015-09-01 08:14:29
7楼2015-08-31 16:02:44
10楼2015-09-01 08:19:15
11楼2015-09-14 11:50:36











回复此楼